CytomX Therapeutics (CTMX) Competitors

$3.78 -0.02 (-0.40%)

Closing price 03:59 PM Eastern

Extended Trading

$3.77 0.00 (-0.13%)

As of 04:10 PM Eastern

CTMX vs. TARS, KOD, IMNM, IRON, and ELVN

Should you buy CytomX Therapeutics stock or one of its competitors? MarketBeat compares CytomX Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CytomX Therapeutics include Tarsus Pharmaceuticals (TARS), Kodiak Sciences (KOD), Immunome (IMNM), Disc Medicine (IRON), and Enliven Therapeutics (ELVN). These companies are all part of the "pharmaceutical products" industry.

How does CytomX Therapeutics compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and CytomX Therapeutics (NASDAQ:CTMX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Tarsus Pharmaceuticals has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market.

CytomX Therapeutics has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	6.21	-$66.42M	-$1.14	N/A
CytomX Therapeutics	$35.54M	18.08	-$17.37M	-$0.41	N/A

Tarsus Pharmaceuticals presently has a consensus price target of $90.67, suggesting a potential upside of 39.06%. CytomX Therapeutics has a consensus price target of $12.78, suggesting a potential upside of 238.48%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 6.6% of CytomX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Tarsus Pharmaceuticals has a net margin of -9.02% compared to CytomX Therapeutics' net margin of -166.40%. Tarsus Pharmaceuticals' return on equity of -14.19% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

In the previous week, Tarsus Pharmaceuticals had 9 more articles in the media than CytomX Therapeutics. MarketBeat recorded 31 mentions for Tarsus Pharmaceuticals and 22 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.75 beat Tarsus Pharmaceuticals' score of 0.16 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	6 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
CytomX Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

CytomX Therapeutics beats Tarsus Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does CytomX Therapeutics compare to Kodiak Sciences?

CytomX Therapeutics (NASDAQ:CTMX) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Kodiak Sciences has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. CytomX Therapeutics' return on equity of -36.61% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Kodiak Sciences	N/A	-253.85%	-81.48%

In the previous week, CytomX Therapeutics had 1 more articles in the media than Kodiak Sciences. MarketBeat recorded 22 mentions for CytomX Therapeutics and 21 mentions for Kodiak Sciences. CytomX Therapeutics' average media sentiment score of 0.75 beat Kodiak Sciences' score of 0.34 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Kodiak Sciences	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CytomX Therapeutics has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$35.54M	18.08	-$17.37M	-$0.41	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 6.6% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 45.9% of Kodiak Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CytomX Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.32, indicating that its share price is 132% more volatile than the broader market.

CytomX Therapeutics presently has a consensus target price of $12.78, indicating a potential upside of 238.48%. Kodiak Sciences has a consensus target price of $42.14, indicating a potential upside of 8.86%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

CytomX Therapeutics beats Kodiak Sciences on 11 of the 15 factors compared between the two stocks.

How does CytomX Therapeutics compare to Immunome?

Immunome (NASDAQ:IMNM) and CytomX Therapeutics (NASDAQ:CTMX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Immunome presently has a consensus target price of $33.45, suggesting a potential upside of 51.91%. CytomX Therapeutics has a consensus target price of $12.78, suggesting a potential upside of 238.48%. Given CytomX Therapeutics' higher probable upside, analysts plainly believe CytomX Therapeutics is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Immunome has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. CytomX Therapeutics' return on equity of -36.61% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-57.71%	-52.69%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

In the previous week, CytomX Therapeutics had 10 more articles in the media than Immunome. MarketBeat recorded 22 mentions for CytomX Therapeutics and 12 mentions for Immunome. Immunome's average media sentiment score of 0.97 beat CytomX Therapeutics' score of 0.75 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

CytomX Therapeutics has higher revenue and earnings than Immunome. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	359.36	-$212.39M	-$2.42	N/A
CytomX Therapeutics	$35.54M	18.08	-$17.37M	-$0.41	N/A

44.6% of Immunome shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Comparatively, 6.6% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Immunome has a beta of 2.11, indicating that its stock price is 111% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the broader market.

Summary

CytomX Therapeutics beats Immunome on 10 of the 16 factors compared between the two stocks.

How does CytomX Therapeutics compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and CytomX Therapeutics (NASDAQ:CTMX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Disc Medicine presently has a consensus target price of $105.30, suggesting a potential upside of 51.02%. CytomX Therapeutics has a consensus target price of $12.78, suggesting a potential upside of 238.48%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CytomX Therapeutics is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Disc Medicine has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. CytomX Therapeutics' return on equity of -36.61% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

In the previous week, CytomX Therapeutics had 7 more articles in the media than Disc Medicine. MarketBeat recorded 22 mentions for CytomX Therapeutics and 15 mentions for Disc Medicine. CytomX Therapeutics' average media sentiment score of 0.75 beat Disc Medicine's score of 0.49 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CytomX Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

CytomX Therapeutics has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
CytomX Therapeutics	$35.54M	18.08	-$17.37M	-$0.41	N/A

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by insiders. Comparatively, 6.6% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Disc Medicine has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the broader market.

Summary

CytomX Therapeutics beats Disc Medicine on 12 of the 15 factors compared between the two stocks.

How does CytomX Therapeutics compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and CytomX Therapeutics (NASDAQ:CTMX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 25.9% of Enliven Therapeutics shares are owned by insiders. Comparatively, 6.6% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Enliven Therapeutics presently has a consensus target price of $53.17, suggesting a potential upside of 23.40%. CytomX Therapeutics has a consensus target price of $12.78, suggesting a potential upside of 238.48%. Given CytomX Therapeutics' higher probable upside, analysts plainly believe CytomX Therapeutics is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, CytomX Therapeutics had 5 more articles in the media than Enliven Therapeutics. MarketBeat recorded 22 mentions for CytomX Therapeutics and 17 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.98 beat CytomX Therapeutics' score of 0.75 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Enliven Therapeutics has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. Enliven Therapeutics' return on equity of -21.04% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

CytomX Therapeutics has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
CytomX Therapeutics	$35.54M	18.08	-$17.37M	-$0.41	N/A

Enliven Therapeutics has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the broader market.

Summary

Enliven Therapeutics and CytomX Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get CytomX Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTMX vs. The Competition

Export

Metric	CytomX Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$642.46M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-9.21	18.81	20.87	25.61
Price / Sales	18.08	181.76	521.62	63.45
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	2.01	6.75	9.86	6.71
Net Income	-$17.37M	$24.11M	$3.55B	$333.77M
7 Day Performance	-5.63%	0.11%	-0.26%	0.40%
1 Month Performance	-16.85%	0.87%	1.39%	4.03%
1 Year Performance	58.61%	78.18%	41.07%	36.33%

CytomX Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTMX CytomX Therapeutics	2.7958 of 5 stars	$3.78 -0.4%	$12.78 +238.5%	+51.6%	$642.46M	$35.54M	N/A	170	Trending News Earnings Report Analyst Forecast Analyst Revision
TARS Tarsus Pharmaceuticals	3.111 of 5 stars	$64.57 +1.5%	$90.67 +40.4%	+56.0%	$2.74B	$451.36M	N/A	50	Analyst Revision
KOD Kodiak Sciences	1.5318 of 5 stars	$42.26 -3.9%	$35.43 -16.2%	+882.9%	$2.73B	N/A	N/A	90	Earnings Report Analyst Upgrade Analyst Revision
IMNM Immunome	3.5015 of 5 stars	$23.33 +2.6%	$33.45 +43.4%	+180.7%	$2.57B	$6.94M	N/A	40	Earnings Report Analyst Forecast Analyst Revision
IRON Disc Medicine	2.4013 of 5 stars	$67.64 +1.1%	$104.80 +54.9%	+51.1%	$2.55B	N/A	N/A	30	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTMX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CytomX Therapeutics (CTMX) Competitors

CTMX vs. TARS, KOD, IMNM, IRON, and ELVN

How does CytomX Therapeutics compare to Tarsus Pharmaceuticals?

Summary

How does CytomX Therapeutics compare to Kodiak Sciences?

Summary

How does CytomX Therapeutics compare to Immunome?

Summary

How does CytomX Therapeutics compare to Disc Medicine?

Summary

How does CytomX Therapeutics compare to Enliven Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX vs. The Competition

CytomX Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CytomX Therapeutics (CTMX) Competitors

CTMX vs. TARS, KOD, IMNM, IRON, and ELVN

How does CytomX Therapeutics compare to Tarsus Pharmaceuticals?

Which has more volatility & risk, TARS or CTMX?

Which has better valuation & earnings, TARS or CTMX?

Do analysts recommend TARS or CTMX?

Do institutionals & insiders hold more shares of TARS or CTMX?

Is TARS or CTMX more profitable?

Does the media prefer TARS or CTMX?

Summary

How does CytomX Therapeutics compare to Kodiak Sciences?

Is CTMX or KOD more profitable?

Does the media favor CTMX or KOD?

Which has better earnings and valuation, CTMX or KOD?

Do insiders and institutionals have more ownership in CTMX or KOD?

Which has more volatility & risk, CTMX or KOD?

Do analysts recommend CTMX or KOD?

Summary

How does CytomX Therapeutics compare to Immunome?

Do analysts prefer IMNM or CTMX?

Is IMNM or CTMX more profitable?

Does the media favor IMNM or CTMX?

Which has higher earnings and valuation, IMNM or CTMX?

Do institutionals and insiders hold more shares of IMNM or CTMX?

Which has more volatility and risk, IMNM or CTMX?

Summary

How does CytomX Therapeutics compare to Disc Medicine?

Do analysts prefer IRON or CTMX?

Is IRON or CTMX more profitable?

Does the media favor IRON or CTMX?

Which has higher earnings and valuation, IRON or CTMX?

Do institutionals and insiders hold more shares of IRON or CTMX?

Which has more volatility and risk, IRON or CTMX?

Summary

How does CytomX Therapeutics compare to Enliven Therapeutics?

Do institutionals and insiders hold more shares of ELVN or CTMX?

Do analysts prefer ELVN or CTMX?

Does the media favor ELVN or CTMX?

Is ELVN or CTMX more profitable?

Which has higher earnings and valuation, ELVN or CTMX?

Which has more volatility and risk, ELVN or CTMX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX vs. The Competition

CytomX Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools